In the last decade, we have been privileged to witness the field of cardiovascular (CV) prevention experience exponential growth. The scientific progress made in the fields of cardiometabolic [[1], [2]] and lifestyle [3,4] sciences, omics [5,6], imaging [7,8], digital health and artificial intelligence [9,10], environmental [11] and implementation [12] disciplines are transforming the field of CV risk assessment, disease prevention, and the delivery of care throughout the life span. The field of CV prevention can no longer be framed as the linear science of risk factor identification and management, but rather shifting towards being a dynamic, multidimensional discipline that integrates biology, behavior, technology, health systems, and policy.
However, the potential of scientific disciplines in healthcare, and especially in prevention, has not always been accompanied by clarity and translation. We are witnessing the risk of cardiometabolic disease manifesting at younger ages [13] rising associated CV burden [14], disparities are growing [15], misinformation is on the rise [16], and the divide between discovery and implementation remains large [17]. The pace of discovery has clearly outstripped progress on relevance and impact [18].
In this context, it becomes not a question of whether journals are witnessing progress in research, but whether they are participating with sufficient focus and momentum to meet current challenges. This issue is even more pressing for journals focusing on prevention. As the gaps in science and actual impact continues to widen, it will not be sufficient to measure the importance of prevention research in terms of innovation [20], but in terms of how it can inform, strengthen, and reduce risk for reducing the overall global burden of CV diseases.
Redefining the role of a cardiovascular prevention journal
Looking forward, capitalizing on the success that Drs. Erin Michos and Nathan Wong have built for us as a trusted platform with growing influence [19], we aspire to position the American Journal of Preventive Cardiology (AJPC) as the global home for prevention science. Building on this momentum, our next chapter must focus on meeting the rising expectations for real-world impact and overcoming persistent gaps between discovery and implementation.
This journey begins with a lot of soul-searching, asking some fundamental questions. What should a prevention journal aspire to be? What type of leadership is needed in the field?
How can AJPC help shape, rather than simply reflect, progress, priorities, and cultural shifts in cardiovascular prevention?
I believe, meeting these challenges will require a fundamental shift in the purpose of our journal.
Historically, our journal, like others, has purely served as a platform for selecting and disseminating scholarly work that is rigorous, authentic, and meaningful. This mission will always remain critical. However, in the current environment that lacks appropriate mechanisms for the timely translation of scholarly work, it is not enough.
Our aspiration should go beyond the dissemination of the most novel research, so that we can make sure that our latest scientific advancements are not only understood but also acted on. In this context, I hope AJPC can become the catalyst for this change, and at the same time, a preferred platform for ideas that will be implemented and challenge quo.
However, this change in direction also comes with a new set of responsibilities. To achieve this, AJPC will have to emphasize what truly matters as well as balance the trade-offs between promoting innovation and application. Most importantly, we must reduce the current unnecessary barriers that are standing in the way of effective and rapid sharing of quality and impactful prevention science with our stakeholders.
In order to meet this mandate, we are intentionally redefining the editorial focus for AJPC in the years ahead: "Lowering barriers, not the bar."
Lowering the barrier, not the bar
This will be the guiding principle in our next phase of evolution. Some may view lowering the bar as a compromise in our standards. On the contrary, our commitment to scientific integrity and relevance has never been greater.
The barriers we seek to remove are procedural rather than scientific. They include the rigidity of the current submission process, the time taken for peer review, and limited communication during the peer review process, as well as cultural biases that favor established voices.
Our goal is to foster an editorial process that is transparent, inclusive, and efficient. We are intentionally creating pathways for high-quality work to be submitted, improved, and shared. It is all about aligning our processes with our values.
Excellence in prevention science, no matter its source, has to be made accessible to those who can benefit from it.
Elevating scientific standards whilst expanding disciplinary scope
Lowering barriers will be matched by an unwavering commitment to scientific excellence. Scientific rigor and relevance will continue to play a fundamental role in all scientific publications. At AJPC, while critical, the science prioritized for publication will not solely be assessed by its novelty, rather we will emphasize research that enhances understanding and informs action.
In order to capture the breadth of the most important topics in prevention, the journal will actively seek out cutting-edge review articles, methodology primers, and concise practice-focused submissions. Studies that speak to the implementation deficit and are representative of various populations will also be encouraged. The journal's editors will work to identify and outline areas of interest for publication via an extensive group of domain-specific editors.
AJPC's aim is not only to provide an outlet for publication, but rather to guide the next set of priorities in the field of prevention science.
A new model of editorial service as scientific stewardship at AJPC
We are grounding our editorial philosophy in respect: respect for the time and intellectual investment of authors, for the judgment and leadership of Associate Editors, and for the expertise and commitment of reviewers. Behind every submission lies months, often years, of work. However, for many of our contributors and participants, the review process is highly opaque, protracted, or depersonalized.
Our hope is to change that in fundamental ways. To support this transformation, I am delighted to introduce an outstanding group of Executive Editors to our journal family: Drs. Martha Gulati, Ron Blankstein, Michael Blaha, and Sadeer Al-Kindi.
Their clinical acumen, academic standing, and passion for prevention science will help inform our strategic vision and steer our journal’s future.
Furthermore, we are moving away from a traditional, arms-length editorial model. Instead, our Associate Editors will become the intellectual guardians for each manuscript, handling a limited number of manuscripts to enable them to engage thoroughly and make informed decisions; allowing them the bandwidth to clearly interact with everyone involved in the specific manuscripts.
We equally value the role of the reviewer for their scholarly contributions, and believe it warrants both recognition and a voice. At AJPC, we will provide reviewers with clear expectations as well as opportunities to inform journal priorities through surveys, annual recognitions, and invited editorials.
We hope by doing so we can cultivate a culture where the entire editorial process, which is heavily dependent our peers' s generosity, is seen not as a burden, but as a valued academic activity that advances impactful prevention science.
Proactive outreach and relationship building at AJPC
We also recognize that shaping the field requires more than reviewing what we receive, but also what we can recruit. In a competitive publishing environment, our ability to lead will depend on proactive engagement with the community we serve. This will require active outreach to researchers, institutions, and networks that we believe are leading the way in advancing impactful prevention science, particularly in emerging, underrepresented, or cross-cutting domains.
In the new era, we will build durable relationships that support both scientific advancement and editorial excellence. We have already started identifying promising work early, including from conference abstracts and research-in-progress, and offer authors clear pathways toward submission. This includes reaching out and encouraging our global networks, community-based initiatives, and early-career investigators to submit their best work to AJPC, which may be overlooked by traditional channels of engagement.
I believe that editorial excellence is not just about what we publish. It is also about who we invite to participate. This outreach strategy reflects our belief that AJPC must remain open, dynamic, and grounded in service to the broader prevention community.
Dissemination as a strategic priority
While publishing strong science is necessary, but no longer sufficient. For research to inform clinical care, guide policy, and impact public health, it must be accessible, visible, and actionable. We also believe that, while publishing quality scientific research will continue to be important, it will not be enough.
For prevention research to impact healthcare, policy, and public health, it needs to be accessible, visible, and actionable.
As part of our commitment, we are launching editorial commentaries [21,22] to accompany select articles [23,24], providing expert context and drawing links across research and practice. We also plan to provide lay summaries, visual abstracts, and tweetorials, and expand our reach on the web. We hope to soon host author interviews, roundtable discussions, and virtual journal club sessions in the coming months.
In addition, we would like to pursue the development of strategies to disseminate our research outside of the academic community. Our aim is to produce materials aimed at the public, in conjunction with ASPC and other partners. These initiatives will evolve over time but reflect our foundational belief that evidence must not exist in a vacuum; it must reach those who likely will act upon it.
Community, mentorship, and the next generation
At AJPC, our commitment goes beyond scientific progress to the nurturing of the community that sustains it. The long-term vitality of preventive cardiology depends on engaging the next generation of investigators, clinicians, and academic leaders. For this, we are strengthening our current Associate Editors team with a wide range of emerging CV prevention trailblazers.
These appointments reflect our belief that the diverse talent bring the essential perspective, relevant expertise, and a strong connection to evolving priorities in prevention.
In addition to the above, we are also investing in the long-term pipeline for academic leadership in cardiovascular prevention. The AJPC Academy, launched in partnership with the Early Career Working Group in ASPC [25], focuses on development in the following three domains: peer review mentorship, dissemination and science communication, and development as academic leaders through authorship. Our focus is to empower young professionals to develop the abilities and confidence to lead.
Community building and capacity development are critical to the sustainability and relevance of AJPC. By investing in people, just as we invest in content, we will cultivate a strong scholarly community for excellence in the present and for leadership in the future.
Strengthening our partnership with ASPC
At AJPC, we have the privilege of being the official journal for the American Society for Preventive Cardiology (ASPC). For us, the relationship is not symbolic; it is strategic [26]. We believe that the mission of ASPC, to reduce the burden of cardiovascular disease through education, advocacy, and the promotion of prevention science, must be strongly reflected and advanced in our journal's content and priorities.
We will continue to issue ASPC-led consensus statements, advisories, and writing group products [27]. Beyond publications, we will collaborate with ASPC leadership on strategic initiatives to refine our future priorities. I believe a strong alignment will strengthen both institutions, with AJPC being responsive to evolving field needs, and at the same time amplify the mission of the society it represents.
Looking ahead
Although I am well aware that the vision outlined above is more of an aspiration than a reality at present, I also firmly believe that such a vision can and must be realized. The future of cardiovascular preventive scientific advancements making real-world changes will be complex, and it demands a sense of urgency and integration.
At AJPC, we take this responsibility seriously. We are committed to lead with purpose, engage with humility, and serve with integrity. I believe that our success will be measured not only by the impact factor alone, but by the influence in shaping prevention practices and understanding.
Our hope is that AJPC becomes a home for those who choose to shape this future: together.
Conflict of interest
Amgen (Advisory Board), Regeneron (Advisory Board), Amsterdam Pharma (Advisory Board) , Merck Sharp & Dolme (Advisory Board), Corsera Health (Consultant), Ionis (Research Grant).
CRediT authorship contribution statement
Khurram Nasir: Conceptualization, Writing – original draft.
Declaration of competing interest
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Khurram Nasir reports a relationship with Corsera Health that includes: consulting or advisory. Khurram Nasir reports a relationship with Amgen Inc that includes: consulting or advisory. Khurram Nasir reports a relationship with Amsterdam Pharma that includes: consulting or advisory.
Khurram Nasir reports a relationship with Merck & Co Inc that includes: consulting or advisory. Khurram Nasir reports a relationship with Regeneron Pharmaceuticals Inc that includes: consulting or advisory. Khurram Nasir reports a relationship with Ionis Pharmaceuticals Inc that includes: funding grants.
If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.